Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass and Behavioral Correlates.

Coplan JD, Lu D, El Sehamy AM, Tang C, Jackowski AP, Abdallah CG, Nemeroff CB, Owens MJ, Mathew SJ, Gorman JM.

Chronic Stress (Thousand Oaks). 2018 Jan-Dec;2. doi: 10.1177/2470547018768450. Epub 2018 Apr 18.

2.

Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder: Investigation of Placebo Response in a Pharmacological Treatment Study of Post-Traumatic Stress Disorder.

Hodgins GE, Blommel JG, Dunlop BW, Iosifescu D, Mathew SJ, Neylan TC, Mayberg HS, Harvey PD.

J Clin Psychopharmacol. 2018 Jun;38(3):200-206. doi: 10.1097/JCP.0000000000000858.

PMID:
29505471
3.

The Neurobiological Mechanisms of Generalized Anxiety Disorder and Chronic Stress.

Patriquin MA, Mathew SJ.

Chronic Stress (Thousand Oaks). 2017 Jan-Dec;1. doi: 10.1177/2470547017703993. Epub 2017 Jun 8.

4.

SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.

Saini M, Verma A, Mathew SJ.

Cell Death Dis. 2018 Feb 14;9(2):237. doi: 10.1038/s41419-018-0261-2.

5.

Neurobiology of the dorsolateral prefrontal cortex in GAD: Aberrant neurometabolic correlation to hippocampus and relationship to anxiety sensitivity and IQ.

Coplan JD, Webler R, Gopinath S, Abdallah CG, Mathew SJ.

J Affect Disord. 2018 Mar 15;229:1-13. doi: 10.1016/j.jad.2017.12.001. Epub 2017 Dec 12.

PMID:
29288871
6.

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment.

Abdallah CG, Averill CL, Salas R, Averill LA, Baldwin PR, Krystal JH, Mathew SJ, Mathalon DH.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):566-574. doi: 10.1016/j.bpsc.2017.04.006.

PMID:
29034354
7.

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G.

Am J Psychiatry. 2018 Feb 1;175(2):150-158. doi: 10.1176/appi.ajp.2017.17040472. Epub 2017 Oct 3. Review.

PMID:
28969441
8.

Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.

Dunlop BW, Binder EB, Iosifescu D, Mathew SJ, Neylan TC, Pape JC, Carrillo-Roa T, Green C, Kinkead B, Grigoriadis D, Rothbaum BO, Nemeroff CB, Mayberg HS.

Biol Psychiatry. 2017 Dec 15;82(12):866-874. doi: 10.1016/j.biopsych.2017.06.024. Epub 2017 Jul 4.

PMID:
28793974
9.

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.

Mathew SJ, Gueorguieva R, Brandt C, Fava M, Sanacora G.

Neuropsychopharmacology. 2017 Dec;42(13):2567-2574. doi: 10.1038/npp.2017.106. Epub 2017 May 29.

PMID:
28553836
10.

Targeting glutamate signalling in depression: progress and prospects.

Murrough JW, Abdallah CG, Mathew SJ.

Nat Rev Drug Discov. 2017 Jul;16(7):472-486. doi: 10.1038/nrd.2017.16. Epub 2017 Mar 17. Review.

PMID:
28303025
11.

The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder.

Abdallah CG, Jackowski A, Salas R, Gupta S, Sato JR, Mao X, Coplan JD, Shungu DC, Mathew SJ.

Neuropsychopharmacology. 2017 Jul;42(8):1739-1746. doi: 10.1038/npp.2017.49. Epub 2017 Mar 8.

12.

A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.

Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, Summergrad P, Nemeroff CB; American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments.

JAMA Psychiatry. 2017 Apr 1;74(4):399-405. doi: 10.1001/jamapsychiatry.2017.0080. Review.

PMID:
28249076
13.

Neurometabolic Abnormalities in Treatment-Resistant Depression.

Mathew SJ, Lijffijt M.

Am J Psychiatry. 2017 Jan 1;174(1):3-5. doi: 10.1176/appi.ajp.2016.16101154. No abstract available.

PMID:
28041002
14.

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

Sanacora G, Johnson MR, Khan A, Atkinson SD, Riesenberg RR, Schronen JP, Burke MA, Zajecka JM, Barra L, Su HL, Posener JA, Bui KH, Quirk MC, Piser TM, Mathew SJ, Pathak S.

Neuropsychopharmacology. 2017 Mar;42(4):844-853. doi: 10.1038/npp.2016.224. Epub 2016 Sep 29.

15.

Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder.

Lijffijt M, Lane SD, Mathew SJ, Stanford MS, Swann AC.

Eur Arch Psychiatry Clin Neurosci. 2017 Oct;267(7):697-707. doi: 10.1007/s00406-016-0734-1. Epub 2016 Sep 23.

PMID:
27662886
16.

Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders.

Sanacora G, Heimer H, Hartman D, Mathew SJ, Frye M, Nemeroff C, Robinson Beale R.

Neuropsychopharmacology. 2017 May;42(6):1179-1181. doi: 10.1038/npp.2016.193. Epub 2016 Sep 19. No abstract available.

17.

Patterns of anterior versus posterior white matter fractional anistotropy concordance in adult nonhuman primates: Effects of early life stress.

Coplan JD, Kolavennu V, Abdallah CG, Mathew SJ, Perera TD, Pantol G, Carpenter D, Tang C.

J Affect Disord. 2016 Mar 1;192:167-75. doi: 10.1016/j.jad.2015.11.049. Epub 2015 Dec 9.

PMID:
26735328
18.

Impact of childhood emotional abuse on neocortical neurometabolites and complex emotional processing in patients with generalized anxiety disorder.

Raparia E, Coplan JD, Abdallah CG, Hof PR, Mao X, Mathew SJ, Shungu DC.

J Affect Disord. 2016 Jan 15;190:414-423. doi: 10.1016/j.jad.2015.09.019. Epub 2015 Oct 23.

PMID:
26551399
19.

Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches.

Al Jurdi RK, Swann A, Mathew SJ.

Curr Psychiatry Rep. 2015 Oct;17(10):81. doi: 10.1007/s11920-015-0614-9. Review.

PMID:
26307033
20.

The Groucho/Transducin-like enhancer of split protein family in animal development.

Agarwal M, Kumar P, Mathew SJ.

IUBMB Life. 2015 Jul;67(7):472-81. doi: 10.1002/iub.1395. Epub 2015 Jul 14. Review.

21.

Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder.

Abdallah CG, Jackowski A, Sato JR, Mao X, Kang G, Cheema R, Coplan JD, Mathew SJ, Shungu DC.

Eur Neuropsychopharmacol. 2015 Aug;25(8):1082-90. doi: 10.1016/j.euroneuro.2015.04.025. Epub 2015 May 5.

22.

Muscle stem cells contribute to myofibres in sedentary adult mice.

Keefe AC, Lawson JA, Flygare SD, Fox ZD, Colasanto MP, Mathew SJ, Yandell M, Kardon G.

Nat Commun. 2015 May 14;6:7087. doi: 10.1038/ncomms8087.

23.

Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies.

Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop BW, Mathew SJ, Khan A, Weisler R, Nelson C, Shelton R, Thase ME, Lane R.

J Clin Psychopharmacol. 2015 Aug;35(4):454-9. doi: 10.1097/JCP.0000000000000335.

PMID:
25961781
24.

Enhanced Olfactory Cortex Connectivity in a Patient With PTSD With Olfactory Hallucinations.

Ridgewell C, Bray A, Curtis K, Velasquez K, Baldwin PR, Fowler JC, Mathew SJ, Salas R.

J Neuropsychiatry Clin Neurosci. 2015;27(2):e170-1. doi: 10.1176/appi.neuropsych.14070156. No abstract available.

PMID:
25923873
25.

A Novel Anxiety and Affective Spectrum Disorder of Mind and Body-The ALPIM (Anxiety-Laxity-Pain-Immune-Mood) Syndrome: A Preliminary Report.

Coplan J, Singh D, Gopinath S, Mathew SJ, Bulbena A.

J Neuropsychiatry Clin Neurosci. 2015;27(2):93-103. doi: 10.1176/appi.neuropsych.14060132.

PMID:
25923849
26.

Does ketamine have anti-suicidal properties? Current status and future directions.

Price RB, Mathew SJ.

CNS Drugs. 2015 Mar;29(3):181-8. doi: 10.1007/s40263-015-0232-4. Review.

27.

Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder.

Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV.

Transl Psychiatry. 2015 Feb 17;5:e509. doi: 10.1038/tp.2015.10.

28.

The promise of ketamine for treatment-resistant depression: current evidence and future directions.

DeWilde KE, Levitch CF, Murrough JW, Mathew SJ, Iosifescu DV.

Ann N Y Acad Sci. 2015 May;1345:47-58. doi: 10.1111/nyas.12646. Epub 2015 Feb 3. Review.

29.

Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid in macaques following early life stress and inverse association with hippocampal volume: preliminary implications for serotonin-related function in mood and anxiety disorders.

Coplan JD, Fulton SL, Reiner W, Jackowski A, Panthangi V, Perera TD, Gorman JM, Huang YY, Tang CY, Hof PR, Kaffman A, Dwork AJ, Mathew SJ, Kaufman J, Mann JJ.

Front Behav Neurosci. 2014 Dec 23;8:440. doi: 10.3389/fnbeh.2014.00440. eCollection 2014.

30.

Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.

Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV.

Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90. doi: 10.1038/npp.2014.298.

31.

Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene.

Coplan JD, Fathy HM, Jackowski AP, Tang CY, Perera TD, Mathew SJ, Martinez J, Abdallah CG, Dwork AJ, Pantol G, Carpenter D, Gorman JM, Nemeroff CB, Owens MJ, Kaffman A, Kaufman J.

Front Behav Neurosci. 2014 Oct 6;8:342. doi: 10.3389/fnbeh.2014.00342. eCollection 2014.

32.

Ketamine safety and tolerability in clinical trials for treatment-resistant depression.

Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW.

J Clin Psychiatry. 2015 Mar;76(3):247-52. doi: 10.4088/JCP.13m08852.

PMID:
25271445
33.

Hippocampal volume and the rapid antidepressant effect of ketamine.

Abdallah CG, Salas R, Jackowski A, Baldwin P, Sato JR, Mathew SJ.

J Psychopharmacol. 2015 May;29(5):591-5. doi: 10.1177/0269881114544776. Epub 2014 Aug 13.

34.

Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports.

Kaye JL, Dunlop BW, Iosifescu DV, Mathew SJ, Kelley ME, Harvey PD.

J Psychiatr Res. 2014 Oct;57:51-7. doi: 10.1016/j.jpsychires.2014.06.002. Epub 2014 Jun 12.

35.

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.

Dunlop BW, Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, Kinkead B, Kutner M, Iosifescu DV, Mathew SJ, Neylan TC, Kilts CD, Nemeroff CB, Mayberg HS.

Trials. 2014 Jun 21;15:240. doi: 10.1186/1745-6215-15-240.

36.

In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder.

Lapidus KA, Gabbay V, Mao X, Johnson A, Murrough JW, Mathew SJ, Shungu DC.

Neurosci Lett. 2014 May 21;569:74-9. doi: 10.1016/j.neulet.2014.03.056. Epub 2014 Apr 2.

37.

Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression.

Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, Soleimani L, Charney DS, Foulkes AL, Mathew SJ.

Depress Anxiety. 2014 Apr;31(4):335-43. doi: 10.1002/da.22253. Epub 2014 Mar 25.

38.

Reduced hippocampal N-acetyl-aspartate (NAA) as a biomarker for overweight.

Coplan JD, Fathy HM, Abdallah CG, Ragab SA, Kral JG, Mao X, Shungu DC, Mathew SJ.

Neuroimage Clin. 2014 Jan 9;4:326-35. doi: 10.1016/j.nicl.2013.12.014. eCollection 2014.

39.

Therapeutic infusions of ketamine: do the psychoactive effects matter?

Dakwar E, Anerella C, Hart CL, Levin FR, Mathew SJ, Nunes EV.

Drug Alcohol Depend. 2014 Mar 1;136:153-7. doi: 10.1016/j.drugalcdep.2013.12.019. Epub 2014 Jan 15.

40.

Glycine transporter-I inhibitors: a new class of antidepressant?

Mathew SJ.

Biol Psychiatry. 2013 Nov 15;74(10):710-1. doi: 10.1016/j.biopsych.2013.08.019. No abstract available.

PMID:
24144323
41.

Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.

Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ 3rd, De La Garza R 2nd, Charney DS, Newton TF, Mathew SJ.

Int J Neuropsychopharmacol. 2014 Feb;17(2):331-6. doi: 10.1017/S1461145713001119. Epub 2013 Oct 8.

42.

Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response.

Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, Perez AM, Mathew SJ, Charney DS, Iosifescu DV, Burdick KE.

Psychopharmacology (Berl). 2013 Sep 11. [Epub ahead of print]

43.

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ.

Am J Psychiatry. 2013 Oct;170(10):1134-42. doi: 10.1176/appi.ajp.2013.13030392.

44.

The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries.

Chang LC, Raty SR, Ortiz J, Bailard NS, Mathew SJ.

CNS Neurosci Ther. 2013 Jun;19(6):390-5. doi: 10.1111/cns.12077. Epub 2013 Mar 11. Review.

45.

Dendritic cell-based vaccines: barriers and opportunities.

Cintolo JA, Datta J, Mathew SJ, Czerniecki BJ.

Future Oncol. 2012 Oct;8(10):1273-99. doi: 10.2217/fon.12.125. Review.

46.

Riluzole effect on occipital cortex: a structural and spectroscopy pilot study.

Abdallah CG, Coplan JD, Jackowski A, Sato JR, Mao X, Shungu DC, Mathew SJ.

Neurosci Lett. 2012 Nov 14;530(1):103-7. doi: 10.1016/j.neulet.2012.09.054. Epub 2012 Oct 5.

47.

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV.

Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27.

48.

A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD.

Abdallah CG, Coplan JD, Jackowski A, Sato JR, Mao X, Shungu DC, Mathew SJ.

Eur Neuropsychopharmacol. 2013 Apr;23(4):276-84. doi: 10.1016/j.euroneuro.2012.05.009. Epub 2012 Jun 26.

49.

Ketamine for depression: where do we go from here?

Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ.

Biol Psychiatry. 2012 Oct 1;72(7):537-47. doi: 10.1016/j.biopsych.2012.05.003. Epub 2012 Jun 16. Review.

50.

The Relationship between Intelligence and Anxiety: An Association with Subcortical White Matter Metabolism.

Coplan JD, Hodulik S, Mathew SJ, Mao X, Hof PR, Gorman JM, Shungu DC.

Front Evol Neurosci. 2012 Feb 1;3:8. doi: 10.3389/fnevo.2011.00008. eCollection 2011.

Supplemental Content

Loading ...
Support Center